Abstract 1201P
Background
Retrospective, single-institution study accessing the efficacy of TEMCAP regiment in pts. with advanced, unresectable progressive GEP-NET as a first or further lines after initial disease progression. Primary endpoint: progression-free survival (PFS), as initial with/without SST analogues previous therapy, PFS as second or further lines therapy using locally evaluation according to RECIST 1.1. Secondary goals: PFS in different subgroups and overall survival (OS).
Methods
54 pts with advanced unresectable, progressive GEP-NET. Mean age 58.0 (SD+/-12.4). All histological confirmed NETs: G1 n=10, G2 n=31, G3 n=13. Standard therapy approach using TEMCAP in all subjects. Disease status and treatment efficiency were evaluated according to localization of primary, initial vs. second or further line systemic therapy, bulky (>25% of liver volume) vs. not bulky liver disease, male vs. female, BMI ≤24 or BM I>24. Standard KM method used to assess PFS and OS for all subjects and in different subgroups. Cox regression model to assess any significant covariates of PFS and OS.
Results
Pancreatic (panNET) n=32, midgut n=8; hindgut n=7 and 7 pts with CUP. PFS for all group 8.0 months (IQR 5.0-15.0), OS from initial diagnosis of GEP-NET 56.8 months (IQR 25.3-96.5); panNET n=32 -PFS=8.0 months (IQR 5.0-16.1), non-pancreas (n=22) PFS=6.2 (IQR 4.0-10.0), n.s. Initial therapy with TEMCAP n=24- PFS=9.2 (6.0-15.0) vs. second or further therapy n=30, PFS=6.0 (IQR 4.1-9.9) n.s. Bulky liver disease (n=31) PFS=7.9 (IQR 5.0-10.0) v.s. non-bulky liver disease (n=23) PFS=7.4 (IQR 4.4-17.0) n.s. Male (n=20) PFS=9.0 (IQR 5.7-15.0), vs. female (n=34) PFS=6.5 (IQR 5.0-11.5), n.s. Median BMI >24.0 PFS=7.0 (IQR 5.0-10.9), vs BMI≤24 PFS=9.0 (IQR 9.0-15.0), n.s. Cox Regression model did not find any significant predictor of improvement in PFS. In Cox regression model of OS indicated that high grade NET (G3) had HR=2.92 (CI 1.17-17.2) of death.
Conclusions
TEMCAP in real world data seems to be a good option in advanced, progressive GEP-NET with PFS=8 months, independently from the primary site, sex, BMI, liver involvement and previous therapy. Overall potential benefits in OS is seen in NETG1 or G2, but not in G3 with HR=2,92.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1170P - Survival outcome prediction of primary melanoma tumours from histology images using deep learning
Presenter: Céline Bossard
Session: Poster session 13
1171P - Evaluation of the transcriptomic presence of tumor associated antigens (TAAs) from antibody drug conjugates (ADCs) and PD-L1 in melanoma: Options for new clinical opportunities
Presenter: Jorge Bartolome
Session: Poster session 13
1172P - Analysis of the microbiome of metastatic melanoma patients with complete response to immunotherapy
Presenter: Marin Golcic
Session: Poster session 13
1173P - NRAS mutation as an independent prognostic factor for resectable Chinese acral melanoma
Presenter: Yu Xu
Session: Poster session 13
1174P - Sex differences in advanced melanoma in Spain: Results from the prospective real-world study GEM 1801
Presenter: Eva Muñoz Couselo
Session: Poster session 13
1175P - Return to work after neoadjuvant versus adjuvant immunotherapy in stage III melanoma patients
Presenter: Judith Lijnsvelt
Session: Poster session 13
1176P - Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study
Presenter: Anna Czarnecka
Session: Poster session 13
1177P - Assessment of tumour burden reduction per photography vs magnetic resonance imaging in patients with locally advanced basal cell carcinoma receiving sonidegib 200 mg
Presenter: Ralf Gutzmer
Session: Poster session 13
1178P - Melanoma incidence rises for pediatrics: 15-year nationwide retrospective cohort study in Korea (2004-2019)
Presenter: Jisu Oh
Session: Poster session 13
1179P - The underestimated skin cancer risk after liver transplantation: A meta-analysis of 147154 patients
Presenter: Amr Ehab El-Qushayri
Session: Poster session 13